| Recruiting | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative B NCT06324240 | Emory University | Phase 1 |
| Recruiting | Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV NCT05417308 | Ohio State University Comprehensive Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable a NCT04616248 | University of Southern California | Phase 1 |
| Recruiting | Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple NCT04348747 | Roswell Park Cancer Institute | Phase 2 |
| Withdrawn | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Can NCT05093387 | Northwestern University | Phase 1 |
| Withdrawn | Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy NCT05315687 | Emory University | Phase 2 |
| Withdrawn | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Ca NCT05244434 | City of Hope Medical Center | N/A |
| Recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer NCT05319873 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Can NCT05215769 | Ohio State University Comprehensive Cancer Center | N/A |
| Withdrawn | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV T NCT05177796 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa NCT04673448 | University of Washington | Phase 1 |
| Active Not Recruiting | CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer NCT05081492 | City of Hope Medical Center | Phase 1 |
| Completed | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel NCT04862585 | Ohio State University Comprehensive Cancer Center | Phase 2 / Phase 3 |
| Completed | Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer NCT04750473 | Emory University | Phase 1 |
| Active Not Recruiting | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases NCT04647916 | SWOG Cancer Research Network | Phase 2 |
| Withdrawn | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer NCT04498520 | Pamela Munster | Phase 1 |
| Terminated | Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast NCT04190056 | University of California, San Francisco | Phase 2 |
| Withdrawn | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positiv NCT04756505 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases NCT04752267 | University of Southern California | EARLY_Phase 1 |
| Recruiting | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Sol NCT04771520 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic NCT04418219 | Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | Nipple Aspirate Fluid in Detecting Breast Cancer NCT03715959 | Ohio State University Comprehensive Cancer Center | N/A |
| Suspended | Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring NCT04906369 | Mayo Clinic | — |
| Withdrawn | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer NCT04351230 | Academic and Community Cancer Research United | Phase 2 |
| Withdrawn | Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal NCT04205071 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study NCT04316117 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Recruiting | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Ca NCT04090567 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study NCT04445844 | Mridula George, MD | Phase 2 |
| Recruiting | Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors NCT04526587 | Roswell Park Cancer Institute | — |
| Withdrawn | Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Recep NCT04585724 | Emory University | Phase 1 |
| Recruiting | Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. NCT04305834 | City of Hope Medical Center | Phase 2 |
| Completed | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer NCT03554044 | University of California, San Francisco | Phase 1 |
| Withdrawn | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer NCT04249167 | Mayo Clinic | EARLY_Phase 1 |
| Suspended | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients NCT03987555 | Wake Forest University Health Sciences | — |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Completed | Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Can NCT03207529 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Terminated | Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Can NCT04256941 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases NCT03796273 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Completed | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating NCT03853707 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Withdrawn | A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer NCT03803761 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis NCT03691493 | Emory University | Phase 2 |
| Completed | Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Communi NCT04297384 | Roswell Park Cancer Institute | N/A |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative NCT03723928 | SWOG Cancer Research Network | N/A |
| Completed | Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Posi NCT03774472 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer NCT03579472 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer NCT03544125 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Brea NCT03524170 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer NCT03106077 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival NCT02364557 | NRG Oncology | Phase 2 / Phase 3 |
| Active Not Recruiting | Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer NCT01334021 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive NCT00338728 | M.D. Anderson Cancer Center | Phase 2 |